Fig. 2
From: How to select IgG subclasses in developing anti-tumor therapeutic antibodies
Working model of CD47xCD20 Bispecific Molecule (IMM0306). IMM0306 targeting CD47xCD20 (Left) is composed of CD20 antibody and the first domain of SIRPα which is connected to the N-terminal of the heavy chain of the antibody. The Fc domain was engineered to have enhanced ADCC/ADCP activity. When administrated, IMM0306 will block the “don't eat me” signal by binding to CD47 and blocking CD47-SIRPα interaction between cancer cells and macrophages, in parallel, it will also strongly activate innate immune cells via Fc-FcγRIIA/FcγRIIIA interaction leading to fully killing of the cancer cells